Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
quinolone · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| quinolone | DRUG | - |
Inclusion Criteria: * Signs \& Symptoms of conjunctivitis Exclusion Criteria: * Under 1 mo. age
Quinolone is an investigational small molecule being developed for the treatment of bacterial conjunctivitis, an infection of the eye's outer membrane. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
Quinolone is being developed by Alcon Inc. (NYSE: ALC), a pharmaceutical company focused on eye care. The drug is currently in Phase 3 clinical trials for bacterial conjunctivitis.
Quinolone is in Phase 3 clinical development for bacterial conjunctivitis. It is an investigational drug and has not yet received regulatory approval. One Phase 3 trial has been completed.
Quinolone has one completed Phase 3 clinical trial, NCT00331916, titled 'AL-15469A for the Treatment of Bacterial Conjunctivitis.' The trial enrolled 600 participants in the United States, including children as young as 1 month.
Yes, quinolone is also known as AL-15469A. The Phase 3 clinical trial NCT00331916, which tested the drug for bacterial conjunctivitis, used the name AL-15469A in its title.